Literature DB >> 125960

Proceedings: Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification.

K Musshoff, H Schmidt-Vollmer.   

Abstract

The prognosis of the non-Hodgkin's lymphomas is determined by 1. the pattern of origin and spread which can be demonstrated in a staging classification, 2, the histopathological type, and 3. the effectiveness and scope of the treatment methods, particularly radio- and chemo-therapy. In the following paper the Ann Arbor Classification, which was originally conceived of for both disease groups (Hodgkin's and non-Hodgkin's lymphomas), is discussed particularly with respect to the applicability and prognostic evaluation for the non-Hodgkin's lymphomas. The Ann Arbor Classification may in essence reflect the oncological characteristics of the non-Hodgkin's accurately; there are, however, a number of findings with qualitative and quantitative differences which defy integration into the Ann Arbor Classification. The qualitative differences consist of the differing lymphatic and extralymphatic origins and their consequence for spread and prognosis. The quantitative differences refer to the varying patterns of distribution of the different stages of spreading, whereby the dissemination stages in the non-Hodgkin's lymphomas are more dependent on the histological form than is the case with the Hodgkin's lymphomas, and thus must play a greater role in the prognostic evaluation and indication for treatment. Suggestions have been made for a modification of the Ann Arbor Staging Classification for the non-Hodgkin's lymphomas.

Entities:  

Mesh:

Year:  1975        PMID: 125960     DOI: 10.1007/bf00573019

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  34 in total

1.  Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.

Authors:  G P Canellos; V T DeVita; R C Young; B A Chabner; P S Schein; R E Johnson
Journal:  Br J Cancer Suppl       Date:  1975-03

2.  Survival and relapse rates in Hodgkin's disease: Stanford experience, 1961-71.

Authors:  H S Kaplan
Journal:  Natl Cancer Inst Monogr       Date:  1973-05

3.  International Symposium on Hodgkin's Disease. Session 6. Survival data and prognosis. Criteria of cure: clinical-pathological correlations.

Authors:  H Rappaport; S B Strum
Journal:  Natl Cancer Inst Monogr       Date:  1973-05

4.  Transformation of reticulum cell sarcoma to acute leukemia.

Authors:  S Lowenbraun; J C Sutherland; M J Feldman; A A Serpick
Journal:  Cancer       Date:  1971-03       Impact factor: 6.860

5.  Prognostic and therapeutic implications of staging in extranodal Hodgkin's disease.

Authors:  K Musshoff
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

6.  Irradiation in the local control of malignant lymphoreticular tumors (non-Hodgkin's malignant lymphoma).

Authors:  J D Cox; R H Koehl; W M Turner; F M King
Journal:  Radiology       Date:  1974-07       Impact factor: 11.105

7.  Occurrence and prognosis of extranodal lymphomas.

Authors:  C Freeman; J W Berg; S J Cutler
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

8.  Contribution of diagnostic laparotomy to staging non-Hodgkin's lymphoma.

Authors:  G E Hanks; L N Terry; J A Bryan; J F Newsome
Journal:  Cancer       Date:  1972-01       Impact factor: 6.860

9.  Reticulum cell sarcoma, an oncologic model for a system of classifying the malignant lymphomas.

Authors:  K Musshoff; H Schmidt-Vollmer; D Merten
Journal:  Eur J Cancer       Date:  1971-10       Impact factor: 9.162

10.  [Prognosis of Hodgkin's disease].

Authors:  J Papillon; P Croizat; L Revol; J L Chassard; E Chassard; A Contamin
Journal:  J Radiol Electrol Med Nucl       Date:  1966 Aug-Sep
View more
  23 in total

1.  Preliminary clinical findings on the Kiel classification of malignant lymphomas.

Authors:  K Musshoff; H Schmidt-Vollmer; K Lennert; W Sandritter
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-12-09

2.  Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.

Authors:  Huilai Zhang; Huijuan Lv; Xiaohui Jia; Ge Hu; Lingzhe Kong; Tingting Zhang; Linyu Li; Yi Pan; Qiongli Zhai; Bin Meng; Xi Wang; Huaqing Wang; Xianhuo Wang
Journal:  Oncol Lett       Date:  2019-05-30       Impact factor: 2.967

3.  [T-zone lymphoma--clinical symptoms, therapy, and prognosis (author's transl)].

Authors:  D Helbron; G Brittinger; K Lennert
Journal:  Blut       Date:  1979-08

Review 4.  Lymphoma of the colon and rectum.

Authors:  M A Richards
Journal:  Postgrad Med J       Date:  1986-07       Impact factor: 2.401

5.  Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas.

Authors:  S Eidt; M Stolte; R Fischer
Journal:  J Clin Pathol       Date:  1994-05       Impact factor: 3.411

6.  Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classification.

Authors:  G Brittinger; U Schmalhorst; H Bartels; H H Fülle; H Gerhartz; G Gremmel; T Grisar; H J Grupp; U Gunzer; D Huhn; K M Koeppen; B Kubanek; H Leopold; H Löffler; G W Löhr; L Nowicki; U Rühl; M Schmidt; A Stacher; H Theml; K Lennert
Journal:  Blut       Date:  1981-09

7.  Diagnostic and therapeutic problems in non-Hodgkin lymphomas.

Authors:  K Musshoff; H Brücher
Journal:  Blut       Date:  1981-09

8.  Investigation results of a comparison made between the Kiel and Rappaport classifications of the non-Hodgkin's lymphomas, together with clinical data.

Authors:  K Musshoff; W von Stotzingen; H Schmidt-Vollmer; H Umbach
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

9.  Novel prognostic scoring system for diffuse large B-cell lymphoma.

Authors:  Pan Zhao; Li Zang; Xiaoying Zhang; Yafang Chen; Zhijie Yue; Hongliang Yang; Haifeng Zhao; Yong Yu; Yafei Wang; Zhigang Zhao; Yizhuo Zhang; Xiaofang Wang
Journal:  Oncol Lett       Date:  2018-02-06       Impact factor: 2.967

10.  [IgD paraproteinemia in immunocytoma].

Authors:  G Papakonstantinou; C Eisenhut; H Füessl; R Hehlmann
Journal:  Klin Wochenschr       Date:  1988-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.